Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation

Diabetes

Volumn 46, Issue 5, 1997, Pages 895-899

  Nakamura, Sakurako ^a   Makita, Zenji ^a   Ishikawa, Shintaro ^b   Yasumura, Koichi ^b   Fujii, Wataru ^a   Yanagisawa, Katsuyuki ^a   Kawata, Tetsuya ^a   Koike, Takao ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b Fujii Memorial Research Institute   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 ISOPROPYLIDENEHYDRAZONO 4 OXO 5 THIAZOLIDINYLACETANILIDE; GLYCOSYLATED PROTEIN; THIAZOLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GLYCATION; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL DRUG ADMINISTRATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN CROSS LINKING; RAT;

EID: 0030906581     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diab.46.5.895     Document Type: Article

References (23)

1. Noth RH, Krolewski AS, Kaysen GA, Meyer TW, Schambelan M: Diabetic nephropathy: hemodynamic basis and implications for disease management. Ann Intern Med 110:795-813, 1989
2. The Diabetes Control and Complications Trial Data Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
3. Monnier VM, Cerami A: Nonenzymatic browning in vivo: possible process for aging of long-lived proteins. Science 211:491-494, 1981
4. Vlassara H, Bucala R, Striker L: Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 70:138-151, 1994
5. Makita Z, Radoff S, Rayfield EJ, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A, Vlassara H: Advanced glycation end products in patients with diabetic nephropathy. N Engl J Med 325:836-842, 1991
6. Makita Z, Bucala R, Rayfleld EJ, Friedman EA, Kaufman AM, Korbet SM, Barth RH, Winston JA, Fuh H, Manogue KR, Cerami A, Vlassara H: Reactive glycosylation endproducts in diabetic uremia and treatment of renal failure. Lancet 343:1519-1522, 1994
7. Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Striker M: Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci 91:11704-11708, 1994
8. Vlassara H, Fuh H, Makita Z, Krungkrai S, Cerami A, Bucala R: Exogenous advanced glycation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc Natl Acad Sci USA 89:12043-12047, 1992
9. Yang CW, Vlassara H, Peten EP, He CJ, Striker GE, Striker LJ: Advanced glycation end products up-regulate gene expression found in glomerular disease. Proc Natl Acad Sci, USA 91:9436-9440, 1994
10. Yang CW, Vlassara H, Striker GE, Striker LJ: Administration of AGEs in vivo induces genes implicated in diabetic glomerulosclerosis. Kidney Int 47 (Suppl. 49):S55-S58, 1995
11. Nicholls K, Mandel TE: Advanced glycosylation end-products in experimental murine diabetic nephropathy: effect of islet isografting and of aminoguanidine. Lab Invest 60:486-491, 1989
12. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G: Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in Streptozocin-induced diabetic rat. Diabetes 40:1328-1334, 1991
13. Ellis NE, Good BH: Prevention of glomerular basement membrane thickening by aminoguanidine in experimental diabetes mellitus. Metabolism 40:1016-1019, 1991
14. Makita Z, Vlassara H, Rayfield E, Cartwright K, Friedman E, Rodby R, Cerami A, Bucala R: Hemoglobin-AGE: a circulating marker of advanced glycation. Science 258:651-653, 1992
15. Makita Z, Vlassara H, Cerami A, Bucala R: Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 267:5133-5138, 1992
16. Kawano K, Hirashima T, Mon S, Saitoh Y, Kurosumi M, Natori T: Spontaneous long-term hyperglycemic rat with diabetic complications: Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 41:1422-1428, 1992
17. Shigematsu H, Kobayashi Y, Tateno S, Hiki Y: Prognostic significance of mesangial sclerosis in IgA nephropathy. Jpn J Nephrol 27:303-309, 1985
18. Vlassara H, Brownlee M, Monogue K, Dinnarello C, Cerami A: Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science 240:1546-1548, 1988
19. Skolnik EY, Yang Z, Makita Z, Radoff S, Kirstein M, Vlassara H: Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodeling and diabetic nephropathy. J Exp Med 174:931-939, 1991
20. Brownlee M, Vlassara H, Kooney P, Ulrich P, Cerami A: Aminoguanidine prevents diabetic-induced arterial wall protein cross-linking. Science 232:1629-1632, 1986
21. Boyd-White J, Williams JC: Effect of cross-linking on matrix permeability: a model for AGE-modifled basement membranes. Diabetes 45:348-353, 1996
22. Niwa T, Katsuzaki T, Momoi T, Miyazaki T, Ogawa H, Saito A, Miyazaki S, Maeda K, Tatemichi N, Takei Y: Modification of 2m with advanced glycation end products as observed in dialysis-related amyloidosis by 3-DG accumulating in uremic serum. Kidney Int 49:861-867, 1996
23. Vasan H, Zhang X, Zhang X, Kapurniotu A, Bernhagen J, Teichberg S, Basgen J, Wagle D, Shih D, Terlecky I, Bucala R, Cerami A, Egan J, Ulrich P: An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 382:275-278, 1996